BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

Emgality gets U.S. approval for episodic cluster headaches FDA approved Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY) to treat episodic cluster headache in adults. The anti-CGRP mAb is already approved as a prophylaxis for...
BioCentury | Apr 4, 2019
Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the osteoarthritis therapy's TGFB1-expressing component is derived from kidney cells rather than cartilage cells as it previously thought. Kolon TissueGene...
BioCentury | Jan 13, 2018
Finance

Choosy investors

Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BioCentury | Jul 13, 2017
Clinical News

TissueGene therapy gets Korean approval for OA

TissueGene Inc. (Rockville, Md.) said Korea approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis (OA) of the knee. Partners Kolon Life Science Inc. (KOSDAQ:102940) and Mundipharma International Ltd. (Dublin, Ireland) will commercialize the...
BioCentury | Jul 12, 2017
Company News

TissueGene therapy gets Korean approval for OA

TissueGene Inc. (Rockville, Md.) said Korea approved regenerative therapy Invossa-K Inj. to treat osteoarthritis of the knee. Partners Kolon Life Science Inc. (KOSDAQ:102940) and Mundipharma International Ltd. (Dublin, Ireland) will commercialize the therapy in that...
BioCentury | Nov 4, 2016
Company News

Kolon, Mitsubishi Tanabe Deal

Kolon granted Mitsubishi exclusive, Japanese rights to develop and commercialize Invossa , which is in development to treat osteoarthritis (OA) of the knee. Kolon will receive ¥2.5 billion ($23.8 million) up front and is eligible for...
BioCentury | Feb 20, 2016
Company News

Management tracks

Metabolic play MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) said Alfred Mann resigned as executive chairman. The board named Lead Director Kent Kresa chairman. Mann will be chairman emeritus and will continue to advise the company. Gastrointestinal...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
Items per page:
1 - 10 of 20
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

Emgality gets U.S. approval for episodic cluster headaches FDA approved Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY) to treat episodic cluster headache in adults. The anti-CGRP mAb is already approved as a prophylaxis for...
BioCentury | Apr 4, 2019
Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the osteoarthritis therapy's TGFB1-expressing component is derived from kidney cells rather than cartilage cells as it previously thought. Kolon TissueGene...
BioCentury | Jan 13, 2018
Finance

Choosy investors

Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BioCentury | Jul 13, 2017
Clinical News

TissueGene therapy gets Korean approval for OA

TissueGene Inc. (Rockville, Md.) said Korea approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis (OA) of the knee. Partners Kolon Life Science Inc. (KOSDAQ:102940) and Mundipharma International Ltd. (Dublin, Ireland) will commercialize the...
BioCentury | Jul 12, 2017
Company News

TissueGene therapy gets Korean approval for OA

TissueGene Inc. (Rockville, Md.) said Korea approved regenerative therapy Invossa-K Inj. to treat osteoarthritis of the knee. Partners Kolon Life Science Inc. (KOSDAQ:102940) and Mundipharma International Ltd. (Dublin, Ireland) will commercialize the therapy in that...
BioCentury | Nov 4, 2016
Company News

Kolon, Mitsubishi Tanabe Deal

Kolon granted Mitsubishi exclusive, Japanese rights to develop and commercialize Invossa , which is in development to treat osteoarthritis (OA) of the knee. Kolon will receive ¥2.5 billion ($23.8 million) up front and is eligible for...
BioCentury | Feb 20, 2016
Company News

Management tracks

Metabolic play MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) said Alfred Mann resigned as executive chairman. The board named Lead Director Kent Kresa chairman. Mann will be chairman emeritus and will continue to advise the company. Gastrointestinal...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
Items per page:
1 - 10 of 20